New hope for bile duct cancer: experimental drug combo enters Mid-Stage trial
NCT ID NCT07151872
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase II trial tests an experimental drug called QLS31905 combined with chemotherapy, with or without another drug (QL2107), in 120 people with advanced biliary tract cancer that has a specific protein (CLDN18.2). The goal is to see if the combination shrinks tumors. Participants must not have had prior treatment for advanced disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS31905 (an experimental drug) combined with chemotherapy (gemcitabine, cisplatin, oxaliplatin, capecitabine) and possibly QL2107
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced biliary tract cancer that has a specific marker (CLDN18.2).
- What could go wrong
- This is an early Phase II trial with only 120 people, so results may not apply to everyone. The drug combination may cause side effects or not work better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.